JP6928809B2 - 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法 - Google Patents

視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法 Download PDF

Info

Publication number
JP6928809B2
JP6928809B2 JP2016529936A JP2016529936A JP6928809B2 JP 6928809 B2 JP6928809 B2 JP 6928809B2 JP 2016529936 A JP2016529936 A JP 2016529936A JP 2016529936 A JP2016529936 A JP 2016529936A JP 6928809 B2 JP6928809 B2 JP 6928809B2
Authority
JP
Japan
Prior art keywords
inh
nmo
composition
treatment
neuromyelitis optica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016529936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540746A5 (enExample
JP2016540746A (ja
Inventor
コリン ブルーム，
コリン ブルーム，
ジェフリー デイノ，
ジェフリー デイノ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2016540746A publication Critical patent/JP2016540746A/ja
Publication of JP2016540746A5 publication Critical patent/JP2016540746A5/ja
Application granted granted Critical
Publication of JP6928809B2 publication Critical patent/JP6928809B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016529936A 2013-11-13 2014-11-12 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法 Active JP6928809B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361903643P 2013-11-13 2013-11-13
US61/903,643 2013-11-13
PCT/US2014/065180 WO2015073514A1 (en) 2013-11-13 2014-11-12 Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019186706A Division JP2020002180A (ja) 2013-11-13 2019-10-10 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法

Publications (3)

Publication Number Publication Date
JP2016540746A JP2016540746A (ja) 2016-12-28
JP2016540746A5 JP2016540746A5 (enExample) 2017-12-21
JP6928809B2 true JP6928809B2 (ja) 2021-09-01

Family

ID=51952046

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016529936A Active JP6928809B2 (ja) 2013-11-13 2014-11-12 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
JP2019186706A Pending JP2020002180A (ja) 2013-11-13 2019-10-10 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
JP2022108932A Pending JP2022125248A (ja) 2013-11-13 2022-07-06 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019186706A Pending JP2020002180A (ja) 2013-11-13 2019-10-10 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
JP2022108932A Pending JP2022125248A (ja) 2013-11-13 2022-07-06 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法

Country Status (7)

Country Link
US (3) US10272142B2 (enExample)
EP (1) EP3068424B1 (enExample)
JP (3) JP6928809B2 (enExample)
BR (1) BR112016010837A8 (enExample)
CA (1) CA2930544A1 (enExample)
ES (1) ES2836137T3 (enExample)
WO (1) WO2015073514A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3068424B1 (en) 2013-11-13 2020-09-09 Shire ViroPharma LLC Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
KR20240121259A (ko) 2021-12-03 2024-08-08 미쓰비시 타나베 파마 코퍼레이션 정보 처리 시스템, 정보 처리 방법, 프로그램

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3666115D1 (en) * 1985-06-29 1989-11-09 Hartmut Griepentrog Machine with magnetic bearing rotor and electric radial field machine
WO2001055390A1 (en) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
ITMI20111390A1 (it) 2011-07-26 2011-10-25 Trivi S R L Gruppo regolabile per la formazione di impasti alimentari
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
CN104205155A (zh) * 2012-03-16 2014-12-10 亚力克恩制药公司 给接受补体抑制剂的患者分配补体抑制药物的方法
PL3013366T3 (pl) * 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
EP3068424B1 (en) 2013-11-13 2020-09-09 Shire ViroPharma LLC Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

Also Published As

Publication number Publication date
BR112016010837A8 (pt) 2020-04-22
EP3068424B1 (en) 2020-09-09
ES2836137T3 (es) 2021-06-24
JP2022125248A (ja) 2022-08-26
JP2016540746A (ja) 2016-12-28
EP3068424A1 (en) 2016-09-21
CA2930544A1 (en) 2015-05-21
US10786557B2 (en) 2020-09-29
US10272142B2 (en) 2019-04-30
WO2015073514A1 (en) 2015-05-21
US20150132296A1 (en) 2015-05-14
US20210236607A1 (en) 2021-08-05
US20190262440A1 (en) 2019-08-29
US11938174B2 (en) 2024-03-26
JP2020002180A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
CA2939506C (en) Methods for treating skin infection by administering an il-4r antagonist
Yong et al. Modulating inflammation and neuroprotection in multiple sclerosis
JP7125353B2 (ja) Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
JP2022125248A (ja) 視神経脊髄炎スペクトル障害の治療に有用な組成物及び方法
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
US20240226039A1 (en) Immune checkpoint inhibitor and hdac inhibitor combination therapy strategy
Saito et al. Adverse functions of Neutrophils are regulated by Neutrophilic Angiotensin-Converting Enzyme in Immune Complex-Medicated Crescentic Glomerulonephritis
US11912772B2 (en) Anti-galectin-9 antibody and methods of use thereof
TWI851911B (zh) 表皮生長因子消耗劑在治療慢性阻塞性肺病中的用途
US20080095778A1 (en) Treatment Of Fungal Infections
WO2024173764A1 (en) Methods of treating hidradenitis suppurativa
CN120285199A (zh) Ncf2在治疗银屑病中的应用
US20070287718A1 (en) Methods for the Treatment of Multiple Myeloma Using Roscovitine
CN117396181A (zh) 抗-IsaA F10抗体的预防和改善特应性皮肤炎的用途
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
KR20130076075A (ko) 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
HK1114766A (en) An anti hsp90 antibody
HK1100320B (en) Treatment of fungal infections
NZ744721B2 (en) Treatment for rheumatoid arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191010

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20191025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191028

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191126

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191127

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191227

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200107

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200409

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201016

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210525

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210611

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210624

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210611

R150 Certificate of patent or registration of utility model

Ref document number: 6928809

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250